Health Canada authorized 16 new prescription drugs and 540 devices in Q3
The regulator also authorized 33 generic and biosimilar drugs from July to September and proposed shorter reviews for medicines for children.
Event / data period: 2026-09
Published: · Updated:
Health Canada reported that it authorized 16 new prescription drugs, 33 generic or biosimilar drugs and 540 new medical devices from July 1 through September 30, 2026. Its quarterly update on October 15 also described pressure on the drug-review process from a growing number of increasingly complex submissions.
The department is prioritizing some generic submissions and advancing changes to clinical-trial rules. A proposed approach for medicines for children and youth would shorten review times from 300 days to as few as 180; the proposal remained under consultation through October 23 and was not a finalized rule.
Data
Health Canada Q3 2026 authorizations
Counts of drugs and medical devices authorized from July 1 through September 30, 2026.
- New prescription drugs
- 16 count
- 2026-09 · Observed
- Generic and biosimilar drugs
- 33 count
- 2026-09 · Observed
- New medical devices
- 540 count
- 2026-09 · Observed
Methodology
Counts are taken from Health Canada’s quarterly release dated October 15, 2026; only categories stated in the source are shown.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Subject suggested from the title or summary: Healthwww.canada.ca ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- Canada · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.canada.ca ↗